Drug intelligence / Profile preview

BI 1820237 + BI 456906

Development stage
Unknown
Lead developer
Boehringer Ingelheim
Modality
Peptides, Small Molecules
Administration
Subcutaneous
01

Overview

BI 1820237 + BI 456906 is an investigational combination of two novel peptide drugs developed for the treatment of overweight and obesity. BI 456906 (also known as survodutide) is a dual agonist at the glucagon-like peptide 1 receptor (GLP-1R) and the glucagon receptor (GCGR), while BI 1820237 is a selective agonist of the neuropeptide Y2 receptor (NPY2R)[4]. Preclinical studies show that BI 1820237 alone causes transient food intake reduction, but its greatest effect appears in combination with BI 456906, where robust and synergistic weight loss is observed above what is possible with either agent alone. The combination is currently under clinical evaluation for its impact on brain activity and body weight regulation in obese/overweight subjects[1][4].

Other names
survodutide + BI 1820237
02

Targets

NPY2R (Neuropeptide Y receptor subtype 2)GLP1R (GLP-1R)GCGR (Glucagon receptor)

Beyond the preview

Go deeper on BI 1820237 + BI 456906.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 1820237 + BI 456906.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call